JANUS HENDERSON GROUP PLC - 24 Jul 2024 Form 4 Insider Report for ARCA biopharma, Inc. (ORKA)

Role
10%+ Owner
Signature
/s/ Michelle Rosenberg, CAO, General Counsel & Company Secretary
Issuer symbol
ORKA
Transactions as of
24 Jul 2024
Net transactions value
+$699,165
Form type
4
Filing time
26 Jul 2024, 10:50:20 UTC
Previous filing
12 Jul 2024
Next filing
20 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABIO Common Stock Purchase $528,000 +165,000 +8.7% $3.20 2,056,312 24 Jul 2024 By Fund F1
transaction ABIO Common Stock Purchase $56,595 +17,800 +0.87% $3.18 2,074,112 24 Jul 2024 By Fund F1
transaction ABIO Common Stock Purchase $22,278 +7,056 +0.34% $3.16 2,081,168 24 Jul 2024 By Fund F1
transaction ABIO Common Stock Purchase $92,292 +30,227 +1.5% $3.05 2,111,395 25 Jul 2024 By Fund F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serve as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.